{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:35:50Z","timestamp":1794713750116,"version":"4.9.1"},"reference-count":50,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight\u2010related comorbidity or obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      TOGETHER\u2010PsA (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      identifier: NCT06588296) is a phase 3b, randomized, 52\u2010week trial in adults with active PsA and overweight (body mass index [BMI] \u226527 to &lt;30) with at least one weight\u2010related comorbidity or obesity (BMI \u226530) using US\u2010approved doses for IXE and TZP. The primary end point was simultaneous achievement of 50% improvement in American College of Rheumatology response criteria (ACR50) and \u226510% weight reduction at 36 weeks. Key secondary outcomes included ACR50. Additional secondary outcomes and patient\u2010reported outcomes (PROs) were assessed. Safety was assessed as adverse events (AEs), treatment\u2010emergent AEs, and serious AEs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 271 participants were randomized (IXE + TZP, n\u00a0=\u00a0138; IXE, n\u00a0=\u00a0133). The primary end point was achieved with significant improvements in the IXE + TZP arm (31.7%) compared to IXE alone (0.8%) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Greater improvements in ACR50 were demonstrated in IXE + TZP (33.5%) versus IXE alone (20.4%) (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.02), with significant early separation at week 4 (nominal\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). IXE + TZP demonstrated nominally significant improvements in ACR20 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), minimal disease activity (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05), and absolute Psoriasis Area and Severity Index score (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01) compared to IXE alone. IXE + TZP demonstrated significant improvements in PROs, including Health Assessment Questionnaire\u2013Disability Index (\u2206 \u22120.2; nominal\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and Functional Assessment of Chronic Illness Therapy\u2013Fatigue (improvement of 3.8; nominal\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01) compared to IXE alone. Safety profiles were consistent with previous studies for each drug.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Participants with active PsA and complex inflammatory\u2010metabolic disease achieved clinically meaningful improvement of PsA, physical function, weight reduction, and quality of life when treated with IXE + TZP compared to IXE alone, with no new safety concerns.<\/jats:p>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/art70134-gra-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.70134","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T19:00:12Z","timestamp":1774724412000},"page":"2089-2101","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial"],"prefix":"10.1002","volume":"78","author":[{"given":"Joseph F.","family":"Merola","sequence":"first","affiliation":[{"name":"Department of Dermatology and Department of Medicine, Division of Rheumatology University of Texas Southwestern Medical Center and O\u2019Donnell School of Public Health  Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip","family":"Mease","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Providence\u2010Swedish Medical Center and University of Washington  Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research  Duncansville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health University of Glasgow  Glasgow United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences University of Oxford  Oxford United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine III Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia E.","family":"Kartman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fischer","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Sun","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00edndaro","family":"Mart\u00ednez\u2010Osuna","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andris","family":"Kronbergs","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purvi","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabela","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Genovese","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine University of Pennsylvania  Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0191-y"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081860"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241271886"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105534"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115779"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204448"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-025-01326-6"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00215-6"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.590749"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201194"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1810-5"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21711"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.1474"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202812"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003157"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03105-8"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40726"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S100940"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"e_1_2_8_23_1","unstructured":"Eli Lilly and Company.Taltz highlights of prescribing information.2024. Updated August 2024.https:\/\/pi.lilly.com\/us\/taltz-uspi.pdf"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00261-0"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez684"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00250-3"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.09.009"},{"key":"e_1_2_8_31_1","unstructured":"Eli Lilly and Company.Zepbound highlights of prescribing information.2025. Updated September 2025.https:\/\/pi.lilly.com\/us\/zepbound-uspi.pdf"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02597-w"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/circ.150.suppl_1.4139912"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24242"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20577"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201000239"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3495"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5974"},{"key":"e_1_2_8_45_1","article-title":"ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials","author":"European Medicines Agency","year":"2020","journal-title":"Committee for Medicinal Products for Human Use"},{"key":"e_1_2_8_46_1","volume-title":"Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products Guidance for Industry","author":"US Food and Drug Administration","year":"2023"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081123"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew326"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2025.105904"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14124124"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02680-y"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70134","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.70134","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:50:36Z","timestamp":1790617836000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.70134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/art.70134"],"URL":"https:\/\/doi.org\/10.1002\/art.70134","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"2026-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}